The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia
Abstract
Overview
Background.
Atherosclerosis occurs as a result of low-density lipoprotein (LDL) deposits oxidation. Endothelial dysfunction is an early process of atherosclerosis. Restoring endothelial lining back to normal by endothelial progenitor
cells (EPCs) is critical for slowing or reversing vascular disease progression. Oxidative stress from hydrogen peroxide
(H2O2) is increased in dyslipidemia so that antioxidant agent is required to prevent destruction of blood vessels.
Objectives.
This study aims to report
Ganoderma lucidum
polysaccharide peptide (PsP) effects in atherogenic
process by measuring H2O2
level, IL-10 level, and EPC number in blood serum, and also intima-media thickness of
aorta in dyslipidemia Wistar rat model by giving them a hypercholesterol diet (HCD).
Materials and methods:
The study was an experimental in vivo post-test with control group design. Thirty-five
Wistar rats (Rattus norwegicus) were divided into five groups (normal diet group, HCD group, and hypercholesterol groups that received 50 mg/kg, 150 mg/kg, and 300 mg/kg bodyweight PsP).
Results.
Each treatment group showed significant results for the administration of PsP using the one-way analysis
of variance test (p<0.050) for the reduction of H2O2
(p = 0.003), levels of IL-10 (p = 0.027), number of EPC in the
blood serum (p = 0.011), and the intima-media thickness of the aorta (p = 0.000). PsP from
G. lucidum
is a potent
antioxidant and may prevent atherogenesis process in patients with dyslipidemia.
Conclusions.
The optimum doses of PsP in this study is 300 mg/kg bodyweight. Further studies are required to
determine the antioxidant effects of PsP
G. lucidum
and its benefits in the management of dyslipidemia.
Keywords
Atherogenesis, Dyslipidemia, EPC, PsP
Article Information
Disclosure
Financial support: No grants or funding have been received for this study.
Correspondence
Titin Andri Wihastuti Department of Biomedicine Faculty of Medicine Brawijaya University Veteran 1 Malang 65112 East Java, Indonesia titinwihastuti@gmail.com
Further Resources
Trending Topic
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce ...
Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable ...
...
...
...
...
...
...
...
...
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
